irradiated haploidentical cells

Irradiated haploidentical cells (IHC) is an experimental cellular immunotherapy developed by Rutgers, The State University of New Jersey, for the treatment of high-risk hematologic malignancies. The therapy involves the infusion of immune cells collected from a partially HLA-matched (haploidentical) relative, such as a parent, child, or sibling. Before administration, these donor cells are irradiated to prevent them from proliferating and causing graft-versus-host disease (GVHD). The primary mechanism of action is to induce a graft-versus-tumor (GVT) effect, where the donor cells recognize and target tumor-associated epitopes on the patient's cancer cells. This approach is being evaluated as a post-transplant strategy to reduce the risk of relapse in patients undergoing autologous or allogeneic hematopoietic stem cell transplantation for conditions including acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma.

Other names

Irradiated haplo-allogeneic cellsIrradiated donor immune cellsIrradiated allogeneic cells